Schrodinger’s Candidate? Achillion’s Sovaprevir On Clinical Hold, But Phase II Combo Trial Continues
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Following findings of elevated liver enzymes in a Phase I drug/drug interaction study, FDA placed Achillion’s protease inhibitor sovaprevir on clinical hold. But the agency is allowing an ongoing Phase II combination trial with NS5A inhibitor ACH-3102 in HCV to continue, probably due in part to clean safety reads from other DDI studies with the protease inhibitor.
You may also be interested in...
Still In The Race: Achillion Says Its HCV Candidates Are “Best-In-Class”
In a year of turmoil in HCV drug development, Achillion has advanced just by staying steady. The biotech could do so with an NS5A inhibitor that shows efficacy in patients with mutated strains of the virus and a strong-performing protease inhibitor.
Viatris And Biocon Launch Bevacizumab Biosimilar In Canada
Viatris and Biocon have introduced their Abevmy biosimilar bevacizumab version of Avastin in Canada. Marking the third oncology biosimilar – and the fourth biosimilar overall – to be launched by Viatris in Canada, the product will face multiple other approved bevacizumab rivals in the market.
ANI ‘On The Cusp Of A Transformation’ Following Cortrophin Launch
ANI Pharmaceuticals appeared confident about its Cortrophin gel launch and integration of Novitium Pharma as it rounded up its Q1 results, but net losses have dampened the company’s share value.